The U.S. Food and Drug Administration had granted Breakthrough Therapy Designation for JNJ-61186372 to treat certain patients with non-small-cell lung cancer. "Janssen Says FDA Grants Breakthrough Therapy Designation to JNJ-6372 to Treat Lung Cancer," at 4:27 p.m. EDT, incorrectly reported that it was for the treatment of certain patients with small-cell lung cancer in the first paragraph.

 

(END) Dow Jones Newswires

March 10, 2020 18:36 ET (22:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Johnson and Johnson